Develop protein-based immunotherapies. Target cancer, autoimmune/inflammatory disorders, and other diseases. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Average growth of 141% a year over the last 4 years. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
This company is not turning a profit, so the market is pricing its sales instead: 75.7× for every dollar of annual revenue.
Analysts' average target sits 15% below today's price.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Over the last 4 years, sales grew about 141% a year on average.
Sales run at $58.9M a year. A small number, but proof the product has real buyers.
There is $327.4M in the vault; even if every debt were paid off, $317.5M would remain.
A loss of $32.2M against $58.9M in annual sales.
The stock trades 15% above the average analyst price target.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.